Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer.
Erika DurinikovaNicole M ReillyKristi BuzoElisa MariellaRosaria ChilàAnnalisa LorenzatoJoao M L DiasGaia GrassoFederica PisatiSimona LambaGiorgio CortiAndrea DegasperiCarlotta CancelliereGianluca MauriPietro AndreiMichael LinnebacherSilvia MarsoniSalvatore SienaAndrea Sartore-BianchiSerena Nik-ZainalFederica Di NicolantonioAlberto BardelliSabrina ArenaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In conclusion, a subset of colorectal cancers refractory to current therapies could benefit from inhibitors of DDR pathways and replication stress. A composite biomarker involving phospho-RPA32 and RAD51 foci, lack of ATM and RAD51C expression, as well as analysis of mutational signatures could be used to identify colorectal cancers likely to respond to ATRi.